Skip to main content
Equibles
GUTS logo

GUTS · Fractyl Health, Inc. · Earnings Call Transcripts & Audio

Track GUTS — free

Use GUTS with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research GUTS.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.54 -0.01 (-1.73%)
Rebalance outlook locked
Going-concern doubt — flagged Aug 10, 2026

Substantial doubt about the company's ability to continue as a going concern.

“As a result, we have concluded that substantial doubt exists about our ability to continue as a going concern for at least one year after the date that these financial statements are issued.”
View the 10-Q filed Aug 10, 2026
Market Cap
$77.30M
Shares
159.18M
Volume · Sep 30 2.15M Avg daily vol (3M) 1.66M

Fractyl Health, Inc. Earnings Call Transcripts

Quarterly earnings calls for Fractyl Health, Inc. (GUTS), with available speaker-labelled transcripts, captured audio replays, call highlights, 8-K earnings releases and periodic filings. Investor days and conferences appear here too.

Pull transcripts and briefs through the earnings call transcript API or MCP →

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▲560% $33,000 −$3.32M '24 Q1 24-05-13 ▼40.3% $43,000 −$17.23M '24 Q2 24-08-14 ▼61.1% $14,000 −$23.17M '24 Q3 24-11-12 LATEST ▼57.1% $3,000 −$24.97M '24 Q4 25-03-03
Conference
Investor event
2026-08-12
Fractyl Health, Inc. (GUTS) August 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q2
2026-07-15
Fractyl Health, Inc. (GUTS) Q2 2026 Earnings Call
Diluted EPS
$-0.16
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q1
2026-05-12
Fractyl Health, Inc. (GUTS) Q1 2026 Earnings Call Transcript
Confident tone IP portfolio GLP-1 market dynamics and post-GLP-1 rebound Pivotal trial execution (Remain One)
Diluted EPS
$0.06
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-03-24
Fractyl Health, Inc. (GUTS) Q4 2025 Earnings Call Transcript
Confident tone Revita dose-response (ablation length) REMAIN-1 pivotal study design and readout timeline Regulatory pathway and FDA feedback
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-12
Fractyl Health, Inc. (GUTS) Q3 2025 Earnings Call Transcript
Confident tone Revita Clinical Data and Durability Remain 1 Pivotal Trial Progress Upcoming Clinical Catalysts and Regulatory Path
Diluted EPS
$-0.71
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-12
Fractyl Health, Inc. (GUTS) Q2 2025 Earnings Call Transcript
Confident tone Revita / REMAIN-1 pivotal study and randomized readout Weight regain after GLP-1 discontinuation (unmet need) German real-world registry durability data
Diluted EPS
$-0.57
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-13
Fractyl Health, Inc. (GUTS) Q1 2025 Earnings Call Transcript
Confident tone Remain-1 pivotal enrollment completion Rejuva / RJVA-001 gene therapy platform Regulatory progress and FDA interactions
Diluted EPS
$-0.49
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-03-03
Fractyl Health, Inc. (GUTS) Q4 2024 Earnings Call Transcript
Confident tone Revita / REMAIN-1 pivotal study in weight maintenance Rejuva gene therapy platform REVEAL-1 open-label early data
Revenue
$3,000*
▼ 57.1% YoY
Gross margin
100.0%
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-12
Fractyl Health, Inc. (GUTS) Q3 2024 Earnings Call Transcript
Confident tone GLP-1 limitations and durability concerns Rejuva gene therapy platform and preclinical data Revita REMAIN-1 pivotal study for weight maintenance
Revenue
$14,000
▼ 61.1% YoY
Diluted EPS
$-0.48
Gross margin
50.0%
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-14
Fractyl Health, Inc. (GUTS) Q2 2024 Earnings Call Transcript
Positive tone Revita Breakthrough Device Designation REMAIN-1 Weight Maintenance Study Rejuva Gene Therapy Platform
Revenue
$43,000
▼ 40.3% YoY
Diluted EPS
$-0.36
Gross margin
44.2%
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-13
Fractyl Health, Inc. (GUTS) Q1 2024 Earnings Call Transcript
Confident tone Revita Remain-1 Pivotal Study in Obesity Revitalize-1 Pivotal Trial in Type 2 Diabetes Rejuva Gene Therapy Platform / RJVA-001
Revenue
$33,000
▲ 560% YoY
Diluted EPS
$-0.17
Gross margin
42.4%
Rev · 4q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Showing 1–11 of 11 earnings calls
Key facts CIK 1572616 CUSIP 35168W103 13F (30d) 3 filings 3 filers Visit website Investor relations